Seeking Alpha

The FDA grants Stemline Therapeutics' (STML -0.1%) SL-401 compound Orphan Drug designation for...

The FDA grants Stemline Therapeutics' (STML -0.1%) SL-401 compound Orphan Drug designation for the treatment of a rare and aggressive blood cancer called blastic plasmacytoid dendritic cell neoplasm, for which there is no effective treatment. The decision adds to SL-401's also Orphan Drug status for acute myeloid leukemia. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|